Not necessarily. I find that most of these patients are already on one before they come to me by their primary or diabetic doctor. I have given a prescription for them personally mainly in patients who are overweight and desire weight loss. At this time I am waiting for more definitive trials on the...

I have not yet, I'm not sure how I as a nephrologist fit into this yet and if I write it will it be covered? But I felt that way too for a short period in the earlier days of SGLT2i, so I suspect it is just a matter of time.

According to KDIGO 2022, GLP-1RA are second line DM Rx (see fig 3: Rossing et al., PMID 36272755); this class of medications still awaiting a CKD-dedicated RCT such as FLOW (Rossing et al., PMID 36651820). However, secondary outcomes of CVOT show kidney protective effects for some GLP-1RAs (non...

I have gained a deeper understanding of the use of GLP1 agonists in the care of CKd patients.